Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down to $15.41

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $15.41, but opened at $14.95. Gyre Therapeutics shares last traded at $15.22, with a volume of 5,521 shares traded.

Gyre Therapeutics Stock Down 1.6 %

The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -0.74 and a beta of 2.11. The company has a 50-day simple moving average of $17.31.

Hedge Funds Weigh In On Gyre Therapeutics

A hedge fund recently bought a new stake in Gyre Therapeutics stock. Northern Trust Corp purchased a new stake in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 24,614 shares of the company’s stock, valued at approximately $632,000. Northern Trust Corp owned 0.97% of Gyre Therapeutics at the end of the most recent quarter. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.